Restoration of Immune Balance with Anish Suri, Ph.D., President and CSO at Cue Biopharma
- Author
- Erin Harris
- Published
- Thu 03 Mar 2022
- Episode Link
- None
We love to hear from our listeners. Send us a message.
Cue Biopharma's Anish Suri, Ph.D., explains why the clinical-stage biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
